Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 1/20 | 0.53 |
| ▸ | SLC40A1 | Q9NP59 | 8/20 | 0.50 |
| ▸ | GLO1 | Q04760 | 4/20 | 0.50 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.50 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.50 |
| ▸ | NFKBIA | P25963 | 2/20 | 0.47 |
| ▸ | RELA | Q04206 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.46 |
| ▸ | MMP2 | P08253 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22764852 | 0.89 | SLC40A1 (0.50) | PLAUSLC40A1GLO1AGTR1PAX8 | |
| SCHEMBL22765006 | 0.88 | TDP1 (0.60) | PLAUSLC40A1GLO1AGTR1PAX8 | |
| SCHEMBL22764853 | 0.85 | PLAU (0.52) | PLAUSLC40A1GLO1AGTR1PAX8 | |
| SCHEMBL30471596 | 0.85 | PLAU (0.52) | PLAUSLC40A1GLO1AGTR1PAX8 | |
| SCHEMBL22765016 | 0.85 | SLC40A1 (0.52) | PLAUSLC40A1GLO1AGTR1PAX8 | |
| SCHEMBL22765113 | 0.84 | TDP1 (0.54) | PLAUSLC40A1GLO1AGTR1PAX8 | |
| SCHEMBL26053610 | 0.82 | KMT2A (0.69) | PLAUSLC40A1GLO1AGTR1PAX8 | |
| SCHEMBL22765214 | 0.80 | TDP1 (0.50) | PLAUSLC40A1GLO1AGTR1PAX8 | |
| SCHEMBL22765051 | 0.79 | SLC40A1 (0.63) | SLC40A1GLO1AGTR1PAX8NFKBIA | |
| SCHEMBL22765224 | 0.78 | SLC40A1 (0.46) | PLAUSLC40A1GLO1AGTR1PAX8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11691949-B2 | Quinoline sulfonamide compounds and their use as antibacterial agents | OTAGO INNOVATION LIMITED (NZ) | 2023-07-04 | — | — | US | disclosed |
| US-20200385354-A1 | Quinoline Sulfonamide Compounds and Their Use as Antibacterial Agents | OTAGO INNOVATION LIMITED (NZ) | 2020-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11691949-B2 | Quinoline sulfonamide compounds and their use as antibacterial agents | NQO2, SDHA, SIRT5 | PLAU 4120/4885SLC40A1 4081/4885GLO1 369/4885 |
| US-20200385354-A1 | Quinoline Sulfonamide Compounds and Their Use as Antibacterial Agents | NQO2, SDHA, SIRT5 | PLAU 4120/4885SLC40A1 4081/4885GLO1 369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.